Indian firms that manufacture active pharmaceutical ingredients (APIs) are gearing up to supply the base ingredient required for producing copies of Novo Nordisk A/S’s weight-loss drugs, which are set to lose patent protection next year in several large markets, Bloomberg reported.
From industry heavyweight Dr. Reddy’s Laboratories Ltd. to suppliers such as Macleods Pharmaceuticals Ltd., companies are preparing to produce bulk semaglutide, the key drug substance used in Novo’s popular treatments — Wegovy for obesity and Ozempic for diabetes.
This preparation highlights India’s role in supporting the supply of generics as patents expire, enabling the development of alternatives to Novo’s blockbuster medicines.
